We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Our knowledge, expertise & publications
Deals & Cases
11 November 2021
GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by re-nowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics AG, from which GlycoEra was spun-out, also participated in this round. The proceeds will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.
VISCHER has been advising GlycoEra since inception including the spin-out and the current financing. The team is led by Matthias Staehelin and includes Pauline Pfirter and Timothy Woodtli (all Corporate/M&A)
Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Deals & Cases
Opt-in for our regular updates, news, views, insights and more.